Can Dynavax's stock rebound after a dreadful 2019?
News & Analysis: Dynavax Technologies
DVAX earnings call for the period ending September 30, 2019.
Dynavax's stock surged higher in August. Can this small-cap biotech keep churning higher?
DVAX earnings call for the period ending June 30, 2019.
Acadia Pharmaceuticals and Dynavax Technologies are having a rough week.
It took another tumble despite enthusiastic analyst upgrades earlier this month.
Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.
Dynavax has been locked into a long-term downward trend, but the bottom might be near. Here's why.
The company's latest restructuring announcement isn't sitting well with investors.
Heplisav-B's commercial launch is starting to ramp up.